Med Page Today
NOVEMBER 16, 2024
(MedPage Today) -- CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and accompanying heart failure with preserved ejection fraction (HFpEF), according to the SUMMIT trial. Incident.
American Heart News - Heart News
NOVEMBER 16, 2024
Research Highlights: In an international trial of 713 adults in nine countries including the U.S. called SUMMIT, participants with heart failure with preserved ejection fraction (HFpEF) and obesity taking tirzepatide for an average of 2 years had.
Med Page Today
NOVEMBER 16, 2024
(MedPage Today) -- CHICAGO -- For patients with ventricular tachycardia (VT) and ischemic cardiomyopathy, going right to catheter ablation improved outcomes compared with trying antiarrhythmic drugs first, the VANISH2 trial showed. Death or.
American Heart News - Heart News
NOVEMBER 16, 2024
Research Highlights: A new, multicenter study demonstrated that ablation treatment may be a better first option than medication for many heart attack survivors who develop abnormal electrical short circuits in their heart, which are episodes of.
HCPLive
NOVEMBER 16, 2024
Reducing systolic blood pressure to less than 120 mmHg lowered the risk of major cardiovascular events for most people with diabetes in the BPROAD trial.
Med Page Today
NOVEMBER 16, 2024
(MedPage Today) -- CHICAGO -- The cardiovascular outcome benefit of a tighter systolic blood pressure target was affirmed in patients with type 2 diabetes in the randomized BPROAD trial from China. A target of less than 120 mm Hg reduced a composite.
HCPLive
NOVEMBER 16, 2024
Stine reviews findings from a posthoc analysis of the NASHFit trial suggesting the impact of exercise on MASH resolution, even without weight loss.
Cardiovascular Update brings together the best content for cardiovascular medicine professionals from the widest variety of industry thought leaders.
JAMA Cardiology
NOVEMBER 16, 2024
This multicenter secondary analysis of the FINEARTS-HF randomized clinical trial examines the treatment effect of finerenone, relative to placebo, on clinical outcomes based on postrandomization potassium levels.
American College of Cardiology
NOVEMBER 16, 2024
In patients with obesity and heart failure with preserved ejection fraction (HFpEF), weekly treatment with tirzepatide over approximately two years reduced the risk of worsening heart failure events, based on findings from the SUMMIT trial.
JAMA Cardiology
NOVEMBER 16, 2024
This prespecified secondary analysis of a randomized clinical trial examines the efficacy and safety of finerenone in women and men with heart failure with mildly reduced ejection fraction and heart failure with preserved ejection fraction.
American Heart News - Heart News
NOVEMBER 16, 2024
Research Highlights: Pharmacists in the Veterans Health Administration System who received feedback on their patients' heart failure medication rates, along with educational tools and targeted information, had a significant increase in the frequency.
American College of Cardiology
NOVEMBER 16, 2024
Intensive treatment to control systolic blood pressure (BP) to less than 120 mmHg significantly reduced the incidence of major cardiovascular events in patients over the age of 50 with type 2 diabetes, based on results from the BPROAD trial.
American Heart News - Heart News
NOVEMBER 16, 2024
Research Highlights: A new software program that uses artificial intelligence to read echocardiograms may reduce the wait times for results and lead to more timely medical care. PanEcho is the first AI system to automatically assess all key areas of.
American College of Cardiology
NOVEMBER 16, 2024
Rivaroxaban did not reduce the incidence of cognitive decline, stroke or transient ischemic attack (TIA) in patients younger than 65 with nonvalvular atrial fibrillation (AFib) and low risk for stroke, according to results from the BRAIN-AF trial.
HCPLive
NOVEMBER 16, 2024
Ankeet Bhatt, MD, MBA, discusses a study he led from AHA 2024 examining the cost-effectiveness of dapagliflozin based on how soon therapy was initiated following diagnosis or hospitalization.
American College of Cardiology
NOVEMBER 16, 2024
Among patients with ischemic cardiomyopathy and ventricular tachycardia (VT), catheter ablation as a first-line strategy over antiarrhythmic drugs (AAD) was associated with a lower risk of the primary outcome, according to results of the VANISH2 trial.
HCPLive
NOVEMBER 16, 2024
Tirzepatide reduced the risk of heart failure hospitalization or cardiovascular death by 38% and improved body weight by up to 21% in the SUMMIT trial.
ECG Guru
NOVEMBER 16, 2024
The Patient: Sixty-year-old man with a complaint of severe substernal chest pain. Denies hx of M.I., but reports feeling short of breath on exertion for about a year. Hx of hypertension, but admits he is non-compliant with his medication. Appears pale and diaphoretic, BP 110/68. The ECG: The rhythm is sinus at 62 bpm. The QRS is slightly wide at 110 ms (.11 seconds), but still within normal limits.
American Heart News - Heart News
NOVEMBER 16, 2024
Research Highlights: In the first large trial of its kind, the anti-clotting medication rivaroxaban did not lower the risk of cognitive decline, stroke or transient ischemic attack (TIA) in people younger than age 65 who had atrial fibrillation (AFib).
Med Page Today
NOVEMBER 16, 2024
(MedPage Today) -- TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech University Health Sciences Center.
American Heart News - Heart News
NOVEMBER 16, 2024
Research Highlights: A study of almost 13,000 adults with Type 2 diabetes and high systolic blood pressure assessed if a more intensive treatment approach with a lower blood pressure goal would decrease the risk of major cardiovascular events,
JAMA Cardiology
NOVEMBER 16, 2024
This randomized clinical trial examines whether a partial cardiac denervation procedure reduces the incidence of postoperative atrial fibrillation among patients undergoing isolated coronary artery bypass grafting (CABG) in China.
American College of Cardiology
NOVEMBER 16, 2024
A single dose of nexiguran ziclumeran (nex-z) in patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM) was associated with a substantial reduction in serum transthyretin (TTR) levels, according to a phase 1, single-group, open-label ongoing study.
HCPLive
NOVEMBER 16, 2024
Cohen explains patient perspectives about how healthcare providers can help address the lack of diversity in chronic HBV clinical trials.
American College of Cardiology
NOVEMBER 16, 2024
People who live in rural areas are dying from cardiovascular disease at a much greater rate than those living in urban areas, according to a report presented at AHA 2024 and simultaneously published in JACC. The report shows that disparities in mortality are greater among younger adults and was more pronounced during the COVID-19 pandemic.
HCPLive
NOVEMBER 16, 2024
At NASPGHAN 2024, Okuno shared findings on reduced parental stress after children’s tube weaning, emphasizing the potential for new outpatient weaning protocols.
American College of Cardiology
NOVEMBER 16, 2024
Left atrial appendage closure (LAAC) in patients at moderate to high risk for stroke who were undergoing catheter atrial fibrillation (AFib) ablation resulted in significantly less bleeding compared with oral anticoagulation, based on findings from the OPTION trial presented at AHA 2024 and simultaneously published in NEJM.
HCPLive
NOVEMBER 16, 2024
Initial catheter ablation achieved a lower risk of a composite primary endpoint event than anti-arrhythmic drug therapy in patients who survived a heart attack.
American College of Cardiology
NOVEMBER 16, 2024
A late-breaking session at AHA 2024 highlighted new research focusing on “Smart Cardiology†innovations, including artificial intelligence (AI), aimed at improving heart health.
HCPLive
NOVEMBER 16, 2024
A single dose of nex-z achieved consistent and rapid reductions in serum TTR levels over 12 months of follow-up in patients with ATTR-CM.
American College of Cardiology
NOVEMBER 16, 2024
The goal of the BRAIN-AF trial was to evaluate the impact of rivaroxaban compared with placebo on preventing cognitive decline, stroke, or TIA among patients with atrial fibrillation (AF).
HCPLive
NOVEMBER 16, 2024
Treatment with elafibranor (Iqirvo) improved prognostic GLOBE and UK-PBC scores as early as week 4 in the phase 3 ELATIVE trial.
American College of Cardiology
NOVEMBER 16, 2024
What are temporal U.S. trends, variability, and clinical outcomes of P2Y12 inhibitor pretreatment in non–ST-segment elevation acute coronary syndrome (NSTE-ACS)?
HCPLive
NOVEMBER 16, 2024
Patients with autoimmune hepatitis who are deficient in vitamin D had worse outcomes than patients with normal vitamin D levels.
HeartRhythm
NOVEMBER 16, 2024
Patients with repaired tetralogy of Fallot are at risk of ventricular tachycardia (VT) and sudden cardiac death. Most VTs arise from 5 slowly conducting anatomic isthmuses (SCAIs; conduction velocity ≤0.5 m/s) bound by the right ventriculotomy, ventricular septal defect patch, and tricuspid and pulmonic valves. Historically, risk stratification electrophysiologic studies involved programmed ventricular stimulation with VT induction guiding implantable cardioverter-defibrillator (ICD) implantatio
HCPLive
NOVEMBER 16, 2024
A-319 has been well-tolerated so far and dose-escalation is ongoing in the phase 1 trial.
The New England Journal of Medicine
NOVEMBER 16, 2024
In this audio interview, Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research being presented at the 2024 American Heart Association Scientific Sessions.
Expert insights. Personalized for you.
111 
Let's personalize your content